ASCO 2024 Abstract for Trial #22-09

A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 22-09

ASCO 2024 Poster for Trial 22-09

Click here to view the ASCO 2024 Poster for Trial 22-09 in Full-Size.

Related Abstracts

Discover more abstracts for our trials.

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

Dec 17, 2024

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Dec 17, 2024

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Dec 17, 2024
See All Posts